Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Condition: Pulmonary Disease, Chronic Obstructive Intervention: Drug: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID Sponsor: AstraZeneca Not yet recruiting - verified September 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials
An Open-Label, Single and Multiple-Ascending Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Subjects
Condition: Pulmonary Disease, Chronic Obstructive Interventions: Drug: Aclidinium Bromide 200 μg; Drug: Aclidinium Bromide 400 μg; Drug: Aclidinium Bromide 800 μg Sponsor: AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials
Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Condition: Pulmonary Disease, Chronic Obstructive Intervention: Drug: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID Sponsor: AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials
An Open-Label, Single and Multiple-Ascending Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Subjects
Condition: Pulmonary Disease, Chronic Obstructive Interventions: Drug: Aclidinium Bromide 200 μg; Drug: Aclidinium Bromide 400 μg; Drug: Aclidinium Bromide 800 μg Sponsor: AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials
Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
Condition: Pulmonary Disease, Chronic Obstructive Interventions: Drug: Aclidinium bromide; Drug: Other COPD medication Sponsors: AstraZeneca; RTI Health Solutions Recruiting - verified September 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 18, 2017 Category: Research Source Type: clinical trials
To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease
Condition: Chronic Obstructive Pulmonary Disease Interventions: Drug: Aclidinium bromide/formoterol fumarate combination; Drug: Standard of Care Sponsors: AstraZeneca; QuintilesIMS, Inc. Not yet recruiting - verified June 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2017 Category: Research Source Type: clinical trials
